The Antifungal and Anti-Pneumocystis Activities of the Novel Compound A3IS (Mycosinate)

A3IS (Mycosinate) is a synthetic product which only contains ingredients found naturally within honey. A3IS is a broad-spectrum antimicrobial product which produces a sustained release of hydrogen peroxide at low but therapeutic levels. The product elicits this release through an enzymatic reaction...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2022-08, Vol.66 (8), p.e0052122
Main Authors: Wiederhold, Nathan P, Patterson, Thomas F, Rebholz, Sandra, Boal, Connell W C, Ehrensberger, Monika, Boyle, Ryan, Cushion, Melanie T
Format: Article
Language:English
Subjects:
Antifungal Agents - pharmacology
Antifungal Agents - therapeutic use
Antimicrobial Chemotherapy
Fluconazole - pharmacology
Fungi
Humans
Microbial Sensitivity Tests
Pneumocystis
Pneumonia, Pneumocystis - drug therapy
Susceptibility
Voriconazole - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A3IS (Mycosinate) is a synthetic product which only contains ingredients found naturally within honey. A3IS is a broad-spectrum antimicrobial product which produces a sustained release of hydrogen peroxide at low but therapeutic levels. The product elicits this release through an enzymatic reaction between glucose oxidase and the substrate glucose once the product is hydrated. As medical uses for different honeys are being re-evaluated, the purpose of this study was to evaluate the effects of A3IS against a comprehensive panel of human pathogens, including Pneumocystis species, providing a unique assessment against a panel of eukaryotic pathogens. Without exception, A3IS exhibited significant efficacy at 50% and 100% inhibitory concentrations against a broad spectrum of human pathogens including yeasts, molds (both hyaline and dematiaceous), and dimorphic fungi. Notably, A3IS was effective against fungal strains with a high level of resistance to fluconazole or voriconazole. The 50% inhibitory concentrations for Pneumocystis carinii and P. murina (surrogates for ) were considered "Marked" and "Moderate" on an established rank scale, and would be considered for studies, based on an established pipeline. These results indicate that A3IS is a novel anti-fungal agent against an extensive range of human fungal pathogens.
ISSN:0066-4804
1098-6596
1098-6596
DOI:10.1128/aac.00521-22